SARAA | Risk of Tuberculosis in Biologic Users for Rheumatic Diseases

By on November 8, 2017

Clive Pettipher and Romela Benitha present the following Study: Risk of Tuberculosis in Biologic Users for Rheumatic Diseases.

clive-pettipher-tuberculosis-rheumatic-diseases
BACKGROUND
To evaluate the rate of tuberculosis (TB) in biologic users for Rheumatic Diseases in South Africa, a TB endemic country, the effectiveness of our latent TB (LTB) screening program, risk factors and clinical outcome.

PROCESS AND METHODS
Documented cases of TB were collected from the South African biologics registry (SABIO), practicing rheumatologists and pharmeceutical companies. A matched control arm evaluated the risk of TB in non-biologics users.

Click here to download the poster with more information.

Dr Clive Pettipher is a leading expert in the field of Arthritis and Rheumatology and established Cape Arthritis and Rheumatology in 2015 in the iconic Busamed Hospital.

He qualified as a specialist physician in Johannesburg in 1998 and rheumatologist in 2000. He completed his fellowship at Chris Hani Baragwanath Hospital, acquiring invaluable training.

He started a private practice at Wilgeheuwel Hospital in 2001 until 2014 in rheumatology. He ran a large biologics clinic with over 200 patients on these life changing therapies. His ongoing special interests include the following
• research in biological therapies in South Africa and currently manages the South African Biologics Registry (SABIO).
• Musculoskeletal imaging - ultrasound of tendons and joints related to rheumatology - trained overseas by the European League Against Rheumatism.

He is honored to be a recent president of the South African Rheumatism and Arthritis Association (SARAA) during which time he published the South African Recommendations for the Management of Rheumatoid Arthritis: 'An algorithm for the standard of care in 2013', SAMJ.

He has also published various articles on tuberculosis in international journals and was awarded the Solly Herwitz academic prize for his research and the best MMed in 2000 at the University of the Witwatersrand. He is currently an advisory board member for Roche, Abbvie and Jansen Pharmaceuticals.